The UAE has reaffirmed that advertisements for medical products require prior regulatory approval, extending scrutiny across traditional and digital media while maintaining a prohibition on endorsements by social media influencers.
The Emirates Drug Establishment (EDE) outlined the requirements at a Medical Product Advertising Customer Council held in Dubai on November 18, emphasising that promotional material cannot be published or circulated without its clearance. The discussions also covered regulated advertising for prescription-only medicines, a category subject to specific controls.
The regulator said the requirements apply to printed advertisements, radio and television promotions, outdoor display screens, websites and social media. Approval is necessary regardless of the medium, and advertisers must ensure that promotional claims reflect authorised product information rather than unsupported promises about effectiveness or safety.
The council placed particular emphasis on the prohibition against using social media influencers to advertise, promote or endorse medical products. That restriction applies even as the authority provides a licensing route for other forms of digital medical advertising, distinguishing permitted promotional channels from endorsements that are expressly barred.
Advertisements must present accurate, clear and non-misleading information, remain consistent with approved indications and disclose relevant risks and side effects. Appropriate disclaimers are required according to the nature of the product and whether the intended audience consists of healthcare professionals or members of the public.
The establishment also stressed that promotional messages must not encourage people to diagnose illnesses themselves or obtain prescription treatments without appropriate supervision by healthcare professionals. Those safeguards are especially important where advertisements may be viewed by consumers without the specialist knowledge needed to assess medical claims.
Participants examined the controls applicable to advertising prescription-only medicines. The EDE described their promotion as permissible under approved regulatory conditions, rather than offering unrestricted access to consumer advertising. Requirements can differ according to the product and the audience to whom the advertisement is directed.
Federal Decree-Law No. 38 of 2024 provides the statutory basis for the approval requirement. Its provisions prohibit medical product advertising by visual, written, audio or social media means without EDE authorisation. They also allow the regulator to restrict advertisements for particular products or confine promotion to specified audiences.
Under the legislation, advertising to the public of controlled or semi-controlled products, hazardous substances and toxic chemical precursors is prohibited, including products intended for veterinary use. The EDE’s published licensing guidance similarly lists those categories among products that cannot be promoted.
The regulator’s licensing service requires applicants to hold the relevant pharmaceutical or healthcare establishment licence. Ordinarily, the advertised medical product must also possess valid EDE marketing authorisation, although specified exemptions from that prerequisite are recognised under the law.
Applicants submit requests through the EDE’s electronic service, using UAE PASS to access the system. They must complete an application, upload supporting documents and the proposed advertising material, and pay the applicable fees. Supporting material can include a printed advertisement design, a video storyboard or an audio script.
The EDE lists a service completion period of three working days and an application fee of Dh100. A separate advertising licence fee varies with the applicant’s activity classification and advertising format. Once approval is granted, the licence number must appear on the advertisement in accordance with the authority’s requirements.
The approval process also requires advertising material to reflect evidence supporting the product’s authorised uses. This means the submitted design and wording are part of the regulatory assessment, not merely the product registration details. Advertisers must account for warnings, the audience and the chosen format before seeking formal permission to distribute a campaign.
The customer council also examined monitoring and inspection arrangements across different media. Where advertisements breach regulatory conditions, the establishment can coordinate with competent authorities to address violations and arrange removal of non-compliant material when necessary.
Officials discussed how applications are reviewed, the documentation required for different formats and ways of resolving incomplete submissions. Representatives of pharmaceutical businesses, healthcare providers and other stakeholders were invited to raise questions about the approval process and the practical difficulties encountered when preparing advertising materials.
The meeting took place at the Government Accelerators Centre in Emirates Towers. Participants offered feedback and suggestions on improving the clarity of procedures and making application requirements easier to follow, as the establishment reviewed how its advertising licensing service operates.
Related Posts
Add A Comment